Beryllium-induced disturbances of the murine immune system reflect some phenomena observed in sarcoidosis

Sibylle Pfeifer, Robert Bartlett, J. Strausz, Sabine Haller, Joachim Müller-Quernheim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Sarcoidosis is a systemic granulomatous disorder of unknown origin. In respect to clinical and immunological characteristics, it is indistinguishable from berylliosis. As an approach to develop a murine model reflecting some aspects of sarcoidosis, we attempted to induce berylliosis in mice by treating inbred F1 mice (C57B16×DBA/2) with 3 mg beryllium sulfate (BeSO4) per kg body weight in- traperitoneally. Either pure BeSO4 or BeSO4 in combination with incomplete Freund’s adjuvant was administered. Alternatively, pure BeSO4 was injected 2 days after a single application of cyclophosphamide (150 mg/kg). The spleen index, the spontaneous and phorbolmyristate acetate (PMA)-induced radical oxygen intermediates (ROI) released by peritoneal macrophages, and the proliferative activity of spleen mononuclear cells in response to BeSO4 and concanavalin A (ConA) were evaluated and compared to the corresponding changes observed in sarcoidosis. In all three modes of BeSO4 treatment, the spontaneous ROI release by peritoneal macrophages was significantly elevated. These elevations were very similar to those observed with alveolar macrophages in active sarcoid alveolitis. After BeSO4 treatment, a small proliferative activity of spleen mononuclear cells in response to BeSO4 could be observed. Further, BeSO4-treated spleen mononuclear cells exhibited a markedly reduced response to ConA stimulation (≈20% of control) which parallels the reduced proliferative capacity of sarcoid peripheral blood mononuclear cells (≈45% of control). This reduction could be abolished by pretreating the mice with cyclophosphamide. BeSO4 treatment in combination with incomplete Freund’s adjuvant resulted in a significant increase of spleen mononuclear cell proliferation (1.9-fold) after in vitro stimulation with BeSO4, and prevented the low responsiveness to ConA. All these findings were maximal after 2 and vanished after 5 weeks. In conclusion, BeSO4 treatment of mice yields immunological disturbances which parallel some im- munopathological phenomena of patients with sarcoidosis.

Original languageEnglish
Pages (from-to)332-339
Number of pages8
JournalInternational Archives of Allergy and Immunology
Volume104
Issue number4
DOIs
Publication statusPublished - 1994

Fingerprint

Beryllium
Sarcoidosis
Immune System
Spleen
Concanavalin A
Berylliosis
Peritoneal Macrophages
Cyclophosphamide
Reactive Oxygen Species
Alveolar Macrophages
Therapeutics
Blood Cells
Acetates
Body Weight
Cell Proliferation

Keywords

  • Beryllium
  • Macrophages
  • Radical oxygen intermediates
  • Sarcoidosis
  • T-cell proliferation

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Beryllium-induced disturbances of the murine immune system reflect some phenomena observed in sarcoidosis. / Pfeifer, Sibylle; Bartlett, Robert; Strausz, J.; Haller, Sabine; Müller-Quernheim, Joachim.

In: International Archives of Allergy and Immunology, Vol. 104, No. 4, 1994, p. 332-339.

Research output: Contribution to journalArticle

Pfeifer, Sibylle ; Bartlett, Robert ; Strausz, J. ; Haller, Sabine ; Müller-Quernheim, Joachim. / Beryllium-induced disturbances of the murine immune system reflect some phenomena observed in sarcoidosis. In: International Archives of Allergy and Immunology. 1994 ; Vol. 104, No. 4. pp. 332-339.
@article{ea652a5e86bb4e0baeb48ceecc431c34,
title = "Beryllium-induced disturbances of the murine immune system reflect some phenomena observed in sarcoidosis",
abstract = "Sarcoidosis is a systemic granulomatous disorder of unknown origin. In respect to clinical and immunological characteristics, it is indistinguishable from berylliosis. As an approach to develop a murine model reflecting some aspects of sarcoidosis, we attempted to induce berylliosis in mice by treating inbred F1 mice (C57B16×DBA/2) with 3 mg beryllium sulfate (BeSO4) per kg body weight in- traperitoneally. Either pure BeSO4 or BeSO4 in combination with incomplete Freund’s adjuvant was administered. Alternatively, pure BeSO4 was injected 2 days after a single application of cyclophosphamide (150 mg/kg). The spleen index, the spontaneous and phorbolmyristate acetate (PMA)-induced radical oxygen intermediates (ROI) released by peritoneal macrophages, and the proliferative activity of spleen mononuclear cells in response to BeSO4 and concanavalin A (ConA) were evaluated and compared to the corresponding changes observed in sarcoidosis. In all three modes of BeSO4 treatment, the spontaneous ROI release by peritoneal macrophages was significantly elevated. These elevations were very similar to those observed with alveolar macrophages in active sarcoid alveolitis. After BeSO4 treatment, a small proliferative activity of spleen mononuclear cells in response to BeSO4 could be observed. Further, BeSO4-treated spleen mononuclear cells exhibited a markedly reduced response to ConA stimulation (≈20{\%} of control) which parallels the reduced proliferative capacity of sarcoid peripheral blood mononuclear cells (≈45{\%} of control). This reduction could be abolished by pretreating the mice with cyclophosphamide. BeSO4 treatment in combination with incomplete Freund’s adjuvant resulted in a significant increase of spleen mononuclear cell proliferation (1.9-fold) after in vitro stimulation with BeSO4, and prevented the low responsiveness to ConA. All these findings were maximal after 2 and vanished after 5 weeks. In conclusion, BeSO4 treatment of mice yields immunological disturbances which parallel some im- munopathological phenomena of patients with sarcoidosis.",
keywords = "Beryllium, Macrophages, Radical oxygen intermediates, Sarcoidosis, T-cell proliferation",
author = "Sibylle Pfeifer and Robert Bartlett and J. Strausz and Sabine Haller and Joachim M{\"u}ller-Quernheim",
year = "1994",
doi = "10.1159/000236688",
language = "English",
volume = "104",
pages = "332--339",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Beryllium-induced disturbances of the murine immune system reflect some phenomena observed in sarcoidosis

AU - Pfeifer, Sibylle

AU - Bartlett, Robert

AU - Strausz, J.

AU - Haller, Sabine

AU - Müller-Quernheim, Joachim

PY - 1994

Y1 - 1994

N2 - Sarcoidosis is a systemic granulomatous disorder of unknown origin. In respect to clinical and immunological characteristics, it is indistinguishable from berylliosis. As an approach to develop a murine model reflecting some aspects of sarcoidosis, we attempted to induce berylliosis in mice by treating inbred F1 mice (C57B16×DBA/2) with 3 mg beryllium sulfate (BeSO4) per kg body weight in- traperitoneally. Either pure BeSO4 or BeSO4 in combination with incomplete Freund’s adjuvant was administered. Alternatively, pure BeSO4 was injected 2 days after a single application of cyclophosphamide (150 mg/kg). The spleen index, the spontaneous and phorbolmyristate acetate (PMA)-induced radical oxygen intermediates (ROI) released by peritoneal macrophages, and the proliferative activity of spleen mononuclear cells in response to BeSO4 and concanavalin A (ConA) were evaluated and compared to the corresponding changes observed in sarcoidosis. In all three modes of BeSO4 treatment, the spontaneous ROI release by peritoneal macrophages was significantly elevated. These elevations were very similar to those observed with alveolar macrophages in active sarcoid alveolitis. After BeSO4 treatment, a small proliferative activity of spleen mononuclear cells in response to BeSO4 could be observed. Further, BeSO4-treated spleen mononuclear cells exhibited a markedly reduced response to ConA stimulation (≈20% of control) which parallels the reduced proliferative capacity of sarcoid peripheral blood mononuclear cells (≈45% of control). This reduction could be abolished by pretreating the mice with cyclophosphamide. BeSO4 treatment in combination with incomplete Freund’s adjuvant resulted in a significant increase of spleen mononuclear cell proliferation (1.9-fold) after in vitro stimulation with BeSO4, and prevented the low responsiveness to ConA. All these findings were maximal after 2 and vanished after 5 weeks. In conclusion, BeSO4 treatment of mice yields immunological disturbances which parallel some im- munopathological phenomena of patients with sarcoidosis.

AB - Sarcoidosis is a systemic granulomatous disorder of unknown origin. In respect to clinical and immunological characteristics, it is indistinguishable from berylliosis. As an approach to develop a murine model reflecting some aspects of sarcoidosis, we attempted to induce berylliosis in mice by treating inbred F1 mice (C57B16×DBA/2) with 3 mg beryllium sulfate (BeSO4) per kg body weight in- traperitoneally. Either pure BeSO4 or BeSO4 in combination with incomplete Freund’s adjuvant was administered. Alternatively, pure BeSO4 was injected 2 days after a single application of cyclophosphamide (150 mg/kg). The spleen index, the spontaneous and phorbolmyristate acetate (PMA)-induced radical oxygen intermediates (ROI) released by peritoneal macrophages, and the proliferative activity of spleen mononuclear cells in response to BeSO4 and concanavalin A (ConA) were evaluated and compared to the corresponding changes observed in sarcoidosis. In all three modes of BeSO4 treatment, the spontaneous ROI release by peritoneal macrophages was significantly elevated. These elevations were very similar to those observed with alveolar macrophages in active sarcoid alveolitis. After BeSO4 treatment, a small proliferative activity of spleen mononuclear cells in response to BeSO4 could be observed. Further, BeSO4-treated spleen mononuclear cells exhibited a markedly reduced response to ConA stimulation (≈20% of control) which parallels the reduced proliferative capacity of sarcoid peripheral blood mononuclear cells (≈45% of control). This reduction could be abolished by pretreating the mice with cyclophosphamide. BeSO4 treatment in combination with incomplete Freund’s adjuvant resulted in a significant increase of spleen mononuclear cell proliferation (1.9-fold) after in vitro stimulation with BeSO4, and prevented the low responsiveness to ConA. All these findings were maximal after 2 and vanished after 5 weeks. In conclusion, BeSO4 treatment of mice yields immunological disturbances which parallel some im- munopathological phenomena of patients with sarcoidosis.

KW - Beryllium

KW - Macrophages

KW - Radical oxygen intermediates

KW - Sarcoidosis

KW - T-cell proliferation

UR - http://www.scopus.com/inward/record.url?scp=0028332958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028332958&partnerID=8YFLogxK

U2 - 10.1159/000236688

DO - 10.1159/000236688

M3 - Article

C2 - 8038611

AN - SCOPUS:0028332958

VL - 104

SP - 332

EP - 339

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 4

ER -